Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine Conditioning for Allo-HCT
NCT01596699Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- May 2012
- Primary completion
- Jun 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of clofarabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia (JMML) and 5 more (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Number of Participants With Treatment-Related Adverse Events as a Measure of Safety and Tolerability up to 5 years. Started May 2012; status: terminated.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)chronic myeloid leukemia (CML)bone marrow failure
Beyond the preview
Go deeper on NCT01596699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01596699.